The COVID-19 Treatment Guidelines Panel’s Stat... - CLL Support
The COVID-19 Treatment Guidelines Panel’s Statement on Omicron Subvariants and Anti-SARS-CoV-2 Monoclonal Antibodies as of 10/19/22
You need to be a member of this community to see this post.
Read more about...
6 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients
This post, prepared in collaboration with @[52122] , draws together some earlier posts...
The failing effectiveness of COVID-19 monoclonal antibodies against BA.1, BA.4-5, BA.4.6, BA.2.75, BJ.1 and BQ.1.1
This post is in response to a couple of recent posts highlighting concerning changes in the...
Clinical Trials of Monoclonal antibodies AZD7442 against SARS=CoV-2 (COVID19) - majority of sites in UK and USA
There are two clinical trials of monoclonal antibodies that target covid19.
AstraZeneca is...
An unusual, potent antibody to SARS-CoV-2 variants is isolated from a recovered patient
Given time, ongoing mutation of the SARS-COV2 virus is likely to produce a super-lineage, at least...
Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infect
#CLLSociety Pfizer and BioNTech’s big news this week of a promising novel (not "live") “RNA”...
Related Posts
"Oral Nirmatrelvir–Ritonavir [ Paxlovid ] as Postexposure Prophylaxis for Covid-19" -- does not do much
Evusheld in the UK
Development of AstraZeneca's SARS-CoV2 spike monoclonal antibodies (AZD7442)
The FDA has authorized the Emergency use of REGEN-COV for the treatment of COVID-19 
Covid treatments in the UK - clinical guide
